Edge's Aneurysm Drug Cuts Hospital Stays, Improves Outcomes
This article was originally published in Scrip
Executive Summary
Edge Therapeutics Inc. reported on Feb. 19 during the International Stroke Conference (ISC) in Los Angeles on that EG-1962 cut 3.5 days from time spent in the intensive care unit (ICU) and doubled the likelihood of favorable outcomes for patients with aneurysmal subarachnoid hemorrhage (aSAH).
You may also be interested in...
Edge 'Devastated' By Phase III Failure of EG-1962, Set To Downsize
Company announces plans for layoffs after Phase III NEWTON 2 study of EG-1962 for subarachnoid hemorrhage goes up in smoke.
Sage’s Dalzanemdor Prospects In Doubt After First Mid-Stage Readout
Dalzanemdor (SAGE-718) showed no difference from placebo in a Phase II Parkinson’s disease study, raising concerns about readouts later this year in Huntington’s and Alzheimer’s diseases.
First Phase III Depression Data For Intra-Cellular’s Caplyta Exceed Expectations
With positive results from the first Phase III trial of lumateperone in major depressive disorder and a second readout expected later this quarter, the company plans a supplemental filing in late 2024.